Form 4: Acelyrin Chief Legal Officer Acquires 525,000 Stock Options

Acelyrin's Chief Legal Officer, Amar Murugan, was granted 525,000 employee stock options at an exercise price of $4.73 on November 25, 2024.

Summary

• Amar Murugan, the Chief Legal Officer of Acelyrin, Inc., acquired 525,000 employee stock options on November 25, 2024.
• The exercise price for these options is $4.73 per share.
• The options vest over time, with 1/4 vesting on November 13, 2025, and the remaining 1/48 vesting monthly thereafter, contingent on continued service.
• The options expire on November 24, 2034.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation event, which is generally viewed neutrally to slightly positive as it aligns executive interests with the company's performance.

Positives

• The grant of stock options to a key executive aligns their interests with the company's long-term success.
• The vesting schedule encourages continued service and commitment from the Chief Legal Officer.

Industry Context

Stock option grants are a common practice for incentivizing executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in publicly traded companies.
• The vesting schedule of 1/4 after one year and the remainder monthly is a typical vesting structure.
• The exercise price of $4.73 is specific to Acelyrin's stock price at the time of the grant.

Stakeholder Impact

• The stock option grant may have a minor positive impact on shareholder sentiment as it aligns executive interests with company performance.

Key Dates

Keywords

stock options, insider trading, executive compensation, equity, Acelyrin, SLRN, vesting